Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma 14Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Lymphoma, B-Cell 8Lymphoma, Mantle-Cell 7Burkitt Lymphoma 7Rhabdomyosarcoma 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 5Leukemia 5Immunoblastic Lymphadenopathy 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Sarcoma, Ewing 3Lymphoma, Primary Effusion 3Sarcoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Osteosarcoma 2Neuroblastoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Hodgkin Disease 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Peripheral Blood Stem Cell Transplantation 13Tacrolimus 7Busulfan 7fludarabine phosphate 6Mycophenolic Acid 6Methotrexate 6Imatinib Mesylate 6Cyclosporine 6Filgrastim 5Cyclophosphamide 5Whole-Body Irradiation 3Decitabine 3Cytarabine 3ponatinib 2nilotinib 2bosutinib 2aldesleukin 2Thiotepa 2Stem Cell Transplantation 2Radiotherapy 2Melphalan 2Flow Cytometry 2Etoposide 2Cord Blood Stem Cell Transplantation 2Blood Specimen Collection 2Arsenic Trioxide 2Antilymphocyte Serum 2venetoclax 1vatalanib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Blast Crisis × Vincristine × Clear all
NCT00015860 2013-06-24

STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡